Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Plans to Grow its Global Patent Application Portfolio to 150-200 within Two Years
LXRP files for tenth patent family, expanding the applicability of its DehydraTECH platform relating to tobacco leaves delivering compounds that may or may not include nicotine LXRP receives three new Australian patents and two new notices of allowance from the U.S.; if all are issued, LXRP would then hold 12 issued patents within its first patent family The company out-licenses its technology that promotes healthier and faster ingestion methods in any country where it already has a patent or is patent-pending Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), which owns the patented DehydraTECH ingestion technology platform, is building its strategic…